Risk factors for response and survival after [90Y-DOTA]-TOC treatment
End point . | Risk factor (unit) . | Odds ratio (unadjusted) . | P . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|
Response to [90Y-DOTA]-TOC therapy | Age (y) | 1.02 (0.96-1.08) | 0.56 | |||||||
Sex | 0.50 (0.08-3.01) | 0.45 | ||||||||
Duration of disease (y) | 1.06 (0.89-1.27) | 0.51 | ||||||||
Calcitonin (pg/mL) | 1.00 (0.98-1.02) | 0.90 | ||||||||
Visual score | 1.02 (0.41-2.53) | 0.96 | ||||||||
End point | Risk factor (unit) | Hazard ratio (unadjusted) | P | Hazard ratio (adjusted)* | P | |||||
Survival from time of diagnosis | Duration of disease (y) | 0.74 (0.63-0.87) | 0.0003 | 0.64 (0.51-0.81) | 0.0003 | |||||
Response | 0.50 (0.16-1.51) | 0.22 | 0.20 (0.05-0.81) | 0.02 | ||||||
Age (y) | 0.99 (0.96-1.03) | 0.60 | 0.97 (0.93-1.01) | 0.09 | ||||||
Cumulative activity (GBq)† | 0.34 (0.13-0.86) | 0.02 | 0.45 (0.17-1.19) | 0.11 | ||||||
Calcitonin (ng/mL) | 1.01 (0.99-1.02) | 0.32 | ||||||||
Sex | 0.67 (0.24-1.80) | 0.43 | ||||||||
Kidney toxicity | 1.36 (0.49-3.78) | 0.56 | ||||||||
Survival from first [90Y-DOTA]-TOC therapy | Calcitonin (ng/mL) | 1.01 (1.00-1.03) | 0.03 | 1.02 (1.00-1.04) | 0.007 | |||||
Kidney toxicity | 0.56 (0.19-1.70) | 0.31 | 1.02 (1.00-1.04) | 0.007 | ||||||
Cumulative activity (GBq)† | 0.41 (0.17-0.97) | 0.04 | 0.24 (0.09-0.69) | 0.008 | ||||||
Response | 0.18 (0.05-0.61) | 0.006 | 0.16 (0.04-0.63) | 0.009 | ||||||
Age (y) | 0.98 (0.94-1.02) | 0.31 | 0.96 (0.93-1.00) | 0.02 | ||||||
Duration of disease (y) | 1.05 (0.97-1.14) | 0.23 | ||||||||
Sex | 0.85 (0.30-2.44) | 0.77 | ||||||||
Time to kidney toxicity | Calcitonin (ng/mL) | 1.01 (0.99-1.03) | 0.26 | |||||||
Age (y) | 1.04 (0.96-1.12) | 0.34 | ||||||||
Duration of disease (y) | 0.89 (0.67-1.18) | 0.41 | ||||||||
Creatinine clearance (mL/min) | 0.99 (0.96-1.02) | 0.47 | ||||||||
Sex | 0.50 (0.04-6.11) | 0.59 | ||||||||
Cumulative activity (GBq)† | 1.16 (0.30-4.46) | 0.83 |
End point . | Risk factor (unit) . | Odds ratio (unadjusted) . | P . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|
Response to [90Y-DOTA]-TOC therapy | Age (y) | 1.02 (0.96-1.08) | 0.56 | |||||||
Sex | 0.50 (0.08-3.01) | 0.45 | ||||||||
Duration of disease (y) | 1.06 (0.89-1.27) | 0.51 | ||||||||
Calcitonin (pg/mL) | 1.00 (0.98-1.02) | 0.90 | ||||||||
Visual score | 1.02 (0.41-2.53) | 0.96 | ||||||||
End point | Risk factor (unit) | Hazard ratio (unadjusted) | P | Hazard ratio (adjusted)* | P | |||||
Survival from time of diagnosis | Duration of disease (y) | 0.74 (0.63-0.87) | 0.0003 | 0.64 (0.51-0.81) | 0.0003 | |||||
Response | 0.50 (0.16-1.51) | 0.22 | 0.20 (0.05-0.81) | 0.02 | ||||||
Age (y) | 0.99 (0.96-1.03) | 0.60 | 0.97 (0.93-1.01) | 0.09 | ||||||
Cumulative activity (GBq)† | 0.34 (0.13-0.86) | 0.02 | 0.45 (0.17-1.19) | 0.11 | ||||||
Calcitonin (ng/mL) | 1.01 (0.99-1.02) | 0.32 | ||||||||
Sex | 0.67 (0.24-1.80) | 0.43 | ||||||||
Kidney toxicity | 1.36 (0.49-3.78) | 0.56 | ||||||||
Survival from first [90Y-DOTA]-TOC therapy | Calcitonin (ng/mL) | 1.01 (1.00-1.03) | 0.03 | 1.02 (1.00-1.04) | 0.007 | |||||
Kidney toxicity | 0.56 (0.19-1.70) | 0.31 | 1.02 (1.00-1.04) | 0.007 | ||||||
Cumulative activity (GBq)† | 0.41 (0.17-0.97) | 0.04 | 0.24 (0.09-0.69) | 0.008 | ||||||
Response | 0.18 (0.05-0.61) | 0.006 | 0.16 (0.04-0.63) | 0.009 | ||||||
Age (y) | 0.98 (0.94-1.02) | 0.31 | 0.96 (0.93-1.00) | 0.02 | ||||||
Duration of disease (y) | 1.05 (0.97-1.14) | 0.23 | ||||||||
Sex | 0.85 (0.30-2.44) | 0.77 | ||||||||
Time to kidney toxicity | Calcitonin (ng/mL) | 1.01 (0.99-1.03) | 0.26 | |||||||
Age (y) | 1.04 (0.96-1.12) | 0.34 | ||||||||
Duration of disease (y) | 0.89 (0.67-1.18) | 0.41 | ||||||||
Creatinine clearance (mL/min) | 0.99 (0.96-1.02) | 0.47 | ||||||||
Sex | 0.50 (0.04-6.11) | 0.59 | ||||||||
Cumulative activity (GBq)† | 1.16 (0.30-4.46) | 0.83 |